+1 858-523-8231
Login | Register
menu
AA Blocks, Building Blocks, Catalysts, Inhibitors
Login | Register
71989-26-9,MFCD00037138
Catalog No.:AA00359C

71989-26-9 | Fmoc-Lys(Boc)-OH

Pack Size
Purity
Availability
Price(USD)
Quantity
  
1g
98%
in stock  
$5.00   $3.00
- +
5g
98%
in stock  
$8.00   $6.00
- +
10g
98%
in stock  
$10.00   $7.00
- +
25g
98%
in stock  
$22.00   $15.00
- +
100g
98%
in stock  
$56.00   $39.00
- +
500g
98%
in stock  
$213.00   $149.00
- +
  • Technical Information
  • Properties
  • Upstream Synthesis Route
  • Downstream Synthesis Route
  • Literature
  • Request for Quotation
  • Download SDS
Technical Information
Catalog Number:
AA00359C
Chemical Name:
Fmoc-Lys(Boc)-OH
CAS Number:
71989-26-9
Molecular Formula:
C26H32N2O6
Molecular Weight:
468.5421
MDL Number:
MFCD00037138
SMILES:
O=C(N[C@H](C(=O)O)CCCCNC(=O)OC(C)(C)C)OCC1c2ccccc2c2c1cccc2
Properties
Properties
 
BP:
685.7°C at 760 mmHg  
Form:
Solid  
MP:
130-135 °C (dec.);  
Refractive Index:
-12 ° (C=1, DMF)  
Storage:
Keep in dry area;Room Temperature;  

Computed Properties
 
Complexity:
684  
Covalently-Bonded Unit Count:
1  
Defined Atom Stereocenter Count:
1  
Defined Bond Stereocenter Count:
0  
Formal Charge:
0  
Heavy Atom Count:
34  
Hydrogen Bond Acceptor Count:
6  
Hydrogen Bond Donor Count:
3  
Isotope Atom Count:
0  
Rotatable Bond Count:
12  
Undefined Atom Stereocenter Count:
0  
Undefined Bond Stereocenter Count:
0  
XLogP3:
4.5  

Upstream Synthesis Route

[1]DaltonTransactions,2005,#4,p.728-734

[1]Chemistry-AEuropeanJournal,2015,vol.21,#12,p.4695-4702

[1]Patent:WO2015/95227,2015,A2,.Locationinpatent:Page/Pagecolumn103;104

[2]OrganicandBiomolecularChemistry,2011,vol.9,#4,p.987-993

[3]JournalofMedicinalChemistry,2018,vol.61,#3,p.989-1000

[1]Chimia,2010,vol.64,#3,p.200-202

[1]JournalofPeptideScience,2017,vol.23,#3,p.202-214

[2]ChemicalandPharmaceuticalBulletin,1999,vol.47,#10,p.1489-1490

[3]EuropeanJournalofOrganicChemistry,2015,vol.2015,#17,p.3767-3770

[4]JournalofMaterialsChemistryB,2015,vol.3,#1,p.119-126

[5]BioorganicandMedicinalChemistryLetters,2016,vol.26,#13,p.2980-2983

Downstream Synthesis Route
122889-11-6    35737-15-6    71989-26-9    35661-38-2   
Cbz-His-OH 
 
(R)-1-((R)-5-Amino-1-{(R)-2-benzyloxy-1-(R)-1-((S)-1-carbamoyl-ethylcarbamoyl)-2-(1H-indol-3-yl)-ethylcarbamoyl-ethylcarbamoyl}-pentylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl-carbamicacidbenzylester 

[1]JournalofMedicinalChemistry,1997,vol.40,p.192-200

35661-40-6    71989-26-9   
1-tert-butoxycarbonyl-N-(9-fluorenyl)methoxycarbonyl-D-tryptophan 
  187223-15-0   
Fmoc-Tyr(Bzl)-O-CH2-Ph(3-OCH3)-O-CH2-polystyreneresin 
 
cyclo(diaminoethylcarbamoyl)HyPro-Phe-D-Trp-Lys-Tyr(Bzl)-Phe 

[1]JournalofMedicinalChemistry,2003,vol.46,p.2334-2344

Fmoc-Rinkresin 
  29022-11-5    68858-20-8    35661-60-0    71989-33-8    71989-23-6    71989-26-9    103213-32-7    71989-35-0    132388-59-1    96402-49-2   
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine 
 
C175H214N21O24PolS3 

[1]JournaloftheAmericanChemicalSociety,2008,vol.130,p.14625-14633

Fmoc-Rinkresin 
  29022-11-5    68858-20-8    35661-60-0    71989-33-8    71989-23-6    71989-26-9    71989-35-0    132388-59-1    132327-80-1    96402-49-2   
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine 
 
C131H176N19O22PolS 

[1]JournaloftheAmericanChemicalSociety,2008,vol.130,p.14625-14633

Fmoc-Rinkresin 
  29022-11-5    68858-20-8    35661-60-0    71989-23-6    71989-26-9    103213-32-7    71989-35-0    132388-59-1    96402-49-2    118358-38-6   
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine 
 
C185H224N21O33PolS3 

[1]JournaloftheAmericanChemicalSociety,2008,vol.130,p.14625-14633

Literature

Title: Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.

Journal: Bioorganic & medicinal chemistry letters 20050301

Title: A novel approach for the solid-phase synthesis of substituted cyclic guanidines, their respective bis analogues, and N-acylated guanidines from N-acylated amino acid amides.

Journal: Journal of combinatorial chemistry 20010101

Quotation Request
Company Name:
*
Contact Person:
*
Email:
*
Quantity Required:
*
Country:
Additional Info:
Submit
SDS
Related Products of 71989-26-9
101555-63-9

101555-63-9

 101555-62-8

101555-62-8

 1018899-99-4

1018899-99-4

 114360-54-2

114360-54-2

 1172579-62-2

1172579-62-2

 117322-30-2

117322-30-2
Building Blocks
More >
Tags:71989-26-9 Molecular Formula|71989-26-9 MDL|71989-26-9 SMILES|71989-26-9 Fmoc-Lys(Boc)-OH
Catalog No.: AA00359C
71989-26-9,MFCD00037138
71989-26-9 | Fmoc-Lys(Boc)-OH
Pack Size： 1g
Purity： 98%
in stock
$5.00 $3.00
Pack Size： 5g
Purity： 98%
in stock
$8.00 $6.00
Pack Size： 10g
Purity： 98%
in stock
$10.00 $7.00
Pack Size： 25g
Purity： 98%
in stock
$22.00 $15.00
Pack Size： 100g
Purity： 98%
in stock
$56.00 $39.00
Pack Size： 500g
Purity： 98%
in stock
$213.00 $149.00
Quantity
- +
Add to Card
Order Now
bulk Quotation Request
Technical Information
Catalog Number: AA00359C
Chemical Name: Fmoc-Lys(Boc)-OH
CAS Number: 71989-26-9
Molecular Formula: C26H32N2O6
Molecular Weight: 468.5421
MDL Number: MFCD00037138
SMILES: O=C(N[C@H](C(=O)O)CCCCNC(=O)OC(C)(C)C)OCC1c2ccccc2c2c1cccc2
Properties
BP: 685.7°C at 760 mmHg  
Form: Solid  
MP: 130-135 °C (dec.);  
Refractive Index: -12 ° (C=1, DMF)  
Storage: Keep in dry area;Room Temperature;  
Complexity: 684  
Covalently-Bonded Unit Count: 1  
Defined Atom Stereocenter Count: 1  
Defined Bond Stereocenter Count: 0  
Formal Charge: 0  
Heavy Atom Count: 34  
Hydrogen Bond Acceptor Count: 6  
Hydrogen Bond Donor Count: 3  
Isotope Atom Count: 0  
Rotatable Bond Count: 12  
Undefined Atom Stereocenter Count: 0  
Undefined Bond Stereocenter Count: 0  
XLogP3: 4.5  
Upstream Synthesis Route
29022-11-5    71989-26-9    109425-51-6    49557-75-7 

[1]DaltonTransactions,2005,#4,p.728-734

108-24-7    71989-26-9    23500-04-1 

[1]Chemistry-AEuropeanJournal,2015,vol.21,#12,p.4695-4702

71989-26-9    2418-95-3 

[1]Patent:WO2015/95227,2015,A2,.Locationinpatent:Page/Pagecolumn103;104

[2]OrganicandBiomolecularChemistry,2011,vol.9,#4,p.987-993

[3]JournalofMedicinalChemistry,2018,vol.61,#3,p.989-1000

71989-26-9    4425-82-5    2418-95-3 

[1]Chimia,2010,vol.64,#3,p.200-202

2418-95-3    82911-69-1    71989-26-9 

[1]JournalofPeptideScience,2017,vol.23,#3,p.202-214

[2]ChemicalandPharmaceuticalBulletin,1999,vol.47,#10,p.1489-1490

[3]EuropeanJournalofOrganicChemistry,2015,vol.2015,#17,p.3767-3770

[4]JournalofMaterialsChemistryB,2015,vol.3,#1,p.119-126

[5]BioorganicandMedicinalChemistryLetters,2016,vol.26,#13,p.2980-2983

Downstream Synthesis Route
122889-11-6    35737-15-6    71989-26-9    35661-38-2   
Cbz-His-OH 
 
(R)-1-((R)-5-Amino-1-{(R)-2-benzyloxy-1-(R)-1-((S)-1-carbamoyl-ethylcarbamoyl)-2-(1H-indol-3-yl)-ethylcarbamoyl-ethylcarbamoyl}-pentylcarbamoyl)-2-(1H-imidazol-4-yl)-ethyl-carbamicacidbenzylester 

[1]JournalofMedicinalChemistry,1997,vol.40,p.192-200

35661-40-6    71989-26-9   
1-tert-butoxycarbonyl-N-(9-fluorenyl)methoxycarbonyl-D-tryptophan 
  187223-15-0   
Fmoc-Tyr(Bzl)-O-CH2-Ph(3-OCH3)-O-CH2-polystyreneresin 
 
cyclo(diaminoethylcarbamoyl)HyPro-Phe-D-Trp-Lys-Tyr(Bzl)-Phe 

[1]JournalofMedicinalChemistry,2003,vol.46,p.2334-2344

Fmoc-Rinkresin 
  29022-11-5    68858-20-8    35661-60-0    71989-33-8    71989-23-6    71989-26-9    103213-32-7    71989-35-0    132388-59-1    96402-49-2   
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine 
 
C175H214N21O24PolS3 

[1]JournaloftheAmericanChemicalSociety,2008,vol.130,p.14625-14633

Fmoc-Rinkresin 
  29022-11-5    68858-20-8    35661-60-0    71989-33-8    71989-23-6    71989-26-9    71989-35-0    132388-59-1    132327-80-1    96402-49-2   
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine 
 
C131H176N19O22PolS 

[1]JournaloftheAmericanChemicalSociety,2008,vol.130,p.14625-14633

Fmoc-Rinkresin 
  29022-11-5    68858-20-8    35661-60-0    71989-23-6    71989-26-9    103213-32-7    71989-35-0    132388-59-1    96402-49-2    118358-38-6   
Nα-(9-fluorenylmethyloxycarbonyl)-Nγ-2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl-L-arginine 
 
C185H224N21O33PolS3 

[1]JournaloftheAmericanChemicalSociety,2008,vol.130,p.14625-14633

Literature fold

Title: Lysine derivatives as potent HIV protease inhibitors. Discovery, synthesis and structure-activity relationship studies.

Journal: Bioorganic & medicinal chemistry letters20050301

Title: A novel approach for the solid-phase synthesis of substituted cyclic guanidines, their respective bis analogues, and N-acylated guanidines from N-acylated amino acid amides.

Journal: Journal of combinatorial chemistry20010101

Related Products of of 71989-26-9
101555-63-9
101555-63-9
101555-62-8
101555-62-8
1018899-99-4
1018899-99-4
114360-54-2
114360-54-2
1172579-62-2
1172579-62-2
117322-30-2
117322-30-2
Building Blocks More >
51857-17-1
51857-17-1
N-Boc-1,6-diaminohexane
AA0035C7 | MFCD00671489
1538-75-6
1538-75-6
Trimethylacetic anhydride
AA0035F4 | MFCD00008842
211495-85-1
211495-85-1
Silanediol, dicyclopentyl-
AA0035I6 | MFCD30534222
30093-29-9
30093-29-9
Tetraethylammonium trifluoroacetate
AA0035LA | MFCD00192470
4168-73-4
4168-73-4
Trihexylphosphine
AA0035O9 | MFCD00015285
17284-97-8
17284-97-8
3-Chloro-6-hydrazinylpyridazine
AA0035R6 | MFCD26743662
212322-56-0
212322-56-0
Ethyl 3-(3-amino-4-(methylamino)-n-(pyridin-2-yl)benzamido)propanoate
AA0035UL | MFCD09833624
354574-56-4
354574-56-4
4-Bromo-2,6-dimethylpyrimidine
AA0035XP | MFCD09038905
6052-10-4
6052-10-4
4,4'-(Ethane-1,2-diylbis(oxy))dianiline
AA003617 | MFCD00444490
80980-89-8
80980-89-8
4-(4-bromophenyl)piperidine
AA00364C | MFCD03426370
Submit
© 2017 AA BLOCKS, INC. All rights reserved.